Daniel Lingwood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Lingwood has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alex K. Shalek
Institute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
1 shared publication Carol Fong
Lymphocyte Interaction Laboratory, Francis Crick Institute, London, England, UK
1 shared publicationCecilia Deantonio
Lymphocyte Interaction Laboratory, Francis Crick Institute, London, England, UK
1 shared publicationDaryl W. Borley
Diagnostic and Molecular Development, hLAB Division, hVIVO PLC, Queen Mary BioEnterprises Innovation Centre, London, England, UK
1 shared publicationDennis R. Burton
Ragon Institute of Massachusetts General Hospital, MIT, and Harvard, Cambridge, MA
1 shared publication- Eric Meffre
Stanford University School of Medicine 1 Department of Immunology and Rheumatology Stanford, CA
1 shared publication
Latest Publications
- Open Access
- 24 July 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (8) , 2471-2490
Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies
Vaccines remain the most effective tool to prevent infectious diseases. Here, we introduce an in vitro booster vaccination approach that relies on antigen-dependent activation of human memory B cells in culture. This stimulation induces antigen-specific B cell proliferation, differentiation of B cells into plasma cells, and robust antibody secretion after a few days of culture. We validated this strategy using cells from healthy donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N1 and newly emergent subtypes such as H5N1 and H7N9. Anti-HA antibodies were cross-reactive against multiple subtypes, and some showed neutralizing activity. Although these antibodies may have arisen as a result of previous influenza infection, we also obtained gp120-reactive antibodies from non–HIV-infected donors, indicating that we can generate antibodies without prior antigenic exposure. Overall, our novel approach can be used to rapidly produce therapeutic antibodies and has the potential to assess the immunogenicity of candidate antigens, which could be exploited in future vaccine development.
- 24 July 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (8) , 2471-2490
Open AccessNovel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies
Vaccines remain the most effective tool to prevent infectious diseases. Here, we introduce an in vitro booster vaccination approach that relies on antigen-dependent activation of human memory B cells in culture. This stimulation induces antigen-specific B cell proliferation, differentiation of B cells into plasma cells, and robust antibody secretion after a few days of culture. We validated this strategy using cells from healthy donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N1 and newly emergent subtypes such as H5N1 and H7N9. Anti-HA antibodies were cross-reactive against multiple subtypes, and some showed neutralizing activity. Although these antibodies may have arisen as a result of previous influenza infection, we also obtained gp120-reactive antibodies from non–HIV-infected donors, indicating that we can generate antibodies without prior antigenic exposure. Overall, our novel approach can be used to rapidly produce therapeutic antibodies and has the potential to assess the immunogenicity of candidate antigens, which could be exploited in future vaccine development.